<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacology of benzodiazepines used to treat anxiety symptoms/disorders</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacology of benzodiazepines used to treat anxiety symptoms/disorders</h1>
<div class="graphic"><div class="figure"><div class="ttl">Pharmacology of benzodiazepines used to treat anxiety symptoms/disorders</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Adult oral total daily dose <span style="white-space: nowrap;">(mg)*</span></td> <td class="subtitle1">Comparative potency <span style="white-space: nowrap;">(mg)<sup>¶</sup></span></td> <td class="subtitle1">Onset after oral dose (hours)</td> <td class="subtitle1">Metabolism</td> <td class="subtitle1">Elimination half-life <span style="white-space: nowrap;">(hours)<sup>Δ</sup></span></td> </tr> <tr> <td>Alprazolam</td> <td>0.5 to 6</td> <td>0.5</td> <td>1</td> <td rowspan="2">CYP3A4 to minimally active metabolites.</td> <td rowspan="2"> <p>11 to 15</p> <p>16 (older adults)</p> <p>20 (hepatic impairment)</p> 22 (obesity) </td> </tr> <tr> <td>Alprazolam extended release</td> <td>0.5 to 6 once daily</td> <td>0.5</td> <td>1</td> </tr> <tr> <td>Bromazepam<sup>◊</sup><sup>§</sup></td> <td>6 to 30</td> <td>7.5</td> <td>1</td> <td>CYP1A2. No active metabolite.</td> <td>8 to 20</td> </tr> <tr> <td>Chlordiazepoxide<sup>§</sup></td> <td>5 to 100</td> <td>10</td> <td>1</td> <td>CYP3A4 to active metabolites.</td> <td> <p>30 to 100</p> Prolonged in older adults and hepatic impairment </td> </tr> <tr> <td>Clonazepam</td> <td>0.5 to 4</td> <td>0.25 to 0.5</td> <td>0.5 to 1</td> <td>CYP3A4. No active metabolite.</td> <td>18 to 50</td> </tr> <tr> <td>Clorazepate</td> <td>15 to 60</td> <td>7.5</td> <td>0.5 to 1</td> <td>CYP3A4 to active metabolite.</td> <td>36 to 200</td> </tr> <tr> <td>Diazepam</td> <td>4 to 40</td> <td>5</td> <td>0.25 to 0.5</td> <td>CYP2C19 and 3A4 to active metabolites.</td> <td> <p>50 to 100</p> Prolonged in older adults and renal or hepatic impairment </td> </tr> <tr> <td>Lorazepam immediate release</td> <td> <p>0.5 to 6</p> 0.5 to 4 (hypnotic) </td> <td>1</td> <td>0.5 to 1</td> <td>Non-CYP glucuronidation in liver. No active metabolite.</td> <td>10 to 14</td> </tr> <tr> <td>Lorazepam extended release</td> <td>1 to 6 mg<sup>¥</sup></td> <td>1</td> <td>0.5 to 1</td> <td>Non-CYP glucuronidation in liver. No active metabolite.</td> <td>13 to 27</td> </tr> <tr> <td>Oxazepam</td> <td> <p>30 to 120</p> 15 to 30 (hypnotic) </td> <td>15 to 30</td> <td>1 to 2</td> <td>Non-CYP glucuronidation in liver. No active metabolite.</td> <td>5 to 15</td> </tr> <tr> <td>Prazepam<sup>◊</sup><sup>§</sup></td> <td>15 to 60</td> <td>15</td> <td>2 to 3</td> <td>CYP3A4 to active metabolites.</td> <td> <p>30 to 200</p> Prolonged in older adults </td> </tr> </tbody></table></div><div class="graphic_lgnd">Data on drug metabolism and activity of metabolite(s) are for assessment of potential for CYP drug interactions and risk of accumulation. Risk of accumulation is greater, and dose reduction necessary, for older or debilitated adults and for patients with renal or hepatic insufficiency.</div><div class="graphic_footnotes">* Range of usual <strong>total</strong> daily dose for treatment of adults with anxiety or panic disorder typically given in divided doses two to four times daily.<br/>
¶ Important: Data shown are approximate equal potencies relative to lorazepam 1 mg orally and are NOT recommendations for initiation of therapy or for conversion between agents.<br/>
Δ Half-life of parent drug and pharmacologically active metabolite, if any.<br/>
◊ Not available in the United States.<br/>
§ Use only when other preferred agents are unavailable or not tolerated.<br/>
¥ To be used only when converting from immediate release lorazepam. Total daily dose is equal to the current total daily dose of immediate release lorazepam. Dose is given once daily in the morning after discontinuing immediate dose lorazepam tablets the night before.</div><div id="graphicVersion">Graphic 65653 Version 13.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
